Annual report [Section 13 and 15(d), not S-K Item 405]

Revenues from Contracts and Significant Customers (Tables)

v3.25.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Year Ended December 31, 

($ in thousands)

    

2024

    

2023

Qbrexza

$

25,114

$

25,410

Accutane

19,407

20,168

Amzeeq

5,009

6,201

Zilxi

1,643

1,962

Other / legacy product revenue

3,961

5,921

Collaboration revenue

1,500

5,229

Revenue – related party

 

41

 

103

Other revenue

1,000

 

19,519

Total net revenue

$

57,675

$

84,513